Medicare billing address
CMS Medicare provider billing file
10500 Antenucci BlvdSuite 101
Garfield Hts, OH 44125
CMS public data · NPI 1952372260
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Jeffrey C Lapeyrolerie, M.D.
Specialty
Credential
M.D.
NPI
1952372260
Primary source state
OH
Data retrieval date
July 27, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Jeffrey C Lapeyrolerie, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
10500 Antenucci BlvdCMS Doctors & Clinicians file
1 Infinity Corporate Centre DrCMS Doctors & Clinicians file
10500 Antenucci BoulevardCMS Doctors & Clinicians file
1730 W 25Th StIn the 2024 CMS provider billing file, this NPI had 714 Medicare beneficiaries and 7,992 total services. The average beneficiary age was 76, and the average HCC risk score was 1.7.
Total Medicare allowed amount
$386,721.82
Total Medicare payment amount
$306,125.61
Medicare beneficiaries
714
Total services
7,992
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
75%
CMS beneficiary-panel share
Chronic kidney disease
45%
CMS beneficiary-panel share
Diabetes
38%
CMS beneficiary-panel share
Ischemic heart disease
36%
CMS beneficiary-panel share
Heart failure
30%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Leuprolide injectable, camcevi, 1 mg | 1,260 | $50.89 |
| Injection, denosumab, 1 mg | 1,080 | $25.92 |
| Manual urinalysis test with examination using microscope, non-automated | 716 | $3.91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 506 | $74.45 |
| Insertion of needle into vein for collection of blood sample | 457 | $8.62 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 424 | $119.56 |
| Psa (prostate specific antigen) measurement, total | 393 | $17.98 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 210 | $85.57 |
| Psa (prostate specific antigen) measurement, free | 187 | $18.02 |
| Injection of drug or substance under skin or into muscle | 158 | $13.27 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1952372260. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Tamsulosin Hcl | Tamsulosin Hcl | 634 | 1,746.8 | $11,050.54 |
| 2 | Cephalexin | Cephalexin | 376 | 376 | $1,188.10 |
| 3 | Finasteride | Finasteride | 258 | 737.9 | $3,983.24 |
| 4 | Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 113 | $597.98 |
| 5 | Xtandi | Enzalutamide | 96 | 96 | $1,448,008.26 |
| 6 | Myrbetriq | Mirabegron | 82 | 130 | $56,791.67 |
| 7 | Bicalutamide | Bicalutamide | 71 | 197.3 | $3,347.77 |
| 8 | Testosterone Cypionate | Testosterone Cypionate | 60 | 74.6 | $1,248.38 |
| 9 | Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 118.5 | $857.43 |
| 10 | Bethanechol Chloride | Bethanechol Chloride | 33 | 69.8 | $3,498.94 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
Js Weill Medical College, Cornell University
Graduation year
1986
Group/practice field
Cleveland Urology Associates, Inc
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.